Market Overview

NuVasive to Release $62.5M from Escrow Following Appeals Court Win

Related NUVA
Benzinga's Top Upgrades
NuVasive Upgraded To Buy At Canaccord On Leverage
Haemonetics (HAE) Shares Tank on 2016 Guidance Cut (Zacks)

NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today the release of $62.5 million from a restricted escrow account in relation to NuVasive's trademark dispute regarding the NeuroVision(R) trade name.

Posted-In: News Legal


Related Articles (NUVA)

Get Benzinga's Newsletters